Curesponse offers an innovative functional test that in combination with rapid genomic sequencing, assists your oncologist in prioritizing and selecting treatment options.
For pharmaceutical companies
Curesponse offers unique expertise and custom solutions for pharmaceutical companies developing cancer drugs. Our unique technology enables evaluation of the potential and activity of drug candidates in active human tissue while maintaining the tumor microenvironment, a key factor affecting drug response and resistance.
cResponse™ personalized drug selection test provides:
· Suggested treatment prioritization results within 3 weeks
· Reliable selection of drugs before they are administered
· Recommendation of the most efficient therapy for each patient
· Significant cost reduction